University of Pittsburgh School of Medicine and UPMC Hillman Cancer Center scientists have discovered a novel subset of ...

Nona Biosciences, a global biotechnology company providing a total solution from "Idea to IND" (I to I™), today announced a ...

University of Pittsburgh School of Medicine and UPMC Hillman Cancer Center scientists have discovered a novel subset of cancer-fighting immune cells that reside outside of their normal neighborhood – ...

The immune systems of cancer patients are highly disrupted, with those who have a higher number of immune cells in their ...

The addition of epcoritamab-bysp to standard chemotherapy significantly improved response and survival for patients with ...

More than 13 years after its initial FDA approval, Pfizer’s blood cancer drug Adcetris has nabbed another regulatory green ...

The FDA has approved a new three-drug combination to treat certain types of an aggressive blood cancer called large B-cell lymphoma (LBCL).

Despite research showing the benefits of circulating tumor DNA as an indicator of disease remission in B-cell lymphoma, ...

Among adults with relapsed or refractory indolent B-cell non-Hodgkin lymphoma, the phase 2 TRANSCEND FL trial met its primary ...

Poor physical performance in patients with non-Hodgkin lymphoma receiving CAR T-cell therapy was linked to worse survival and ...

The immune systems of cancer patients are highly disrupted, with those who have a higher number of immune cells in their blood having a better survival rate, finds a new study that uses a pioneering ...